Oxidative stress, resulting from an imbalance between oxidation and antioxidation activities, plays a pivotal role in the pathogenesis of AD
SLC12A8 has been proposed as an NMN transporter into the cell 70 , but this is still debated 71,72

Patients undergoing tirzepatide therapy commonly experience: Improved blood pressure: reductions in systolic and diastolic blood pressure have been observed across tirzepatide clinical trials Better cholesterol profiles: reductions in LDL and triglycerides, with improvements in HDL Improved blood glucose regulation: tirzepatide significantly improves insulin sensitivity and reduces fasting glucose, even in patients without diabetes Reduction in waist circumference: visceral fat reduction, which is directly associated with reduced cardiovascular and metabolic risk Preservation of lean muscle mass: unlike traditional caloric restriction, which often results in 2530% of weight loss coming from muscle, tirzepatide promotes preferential fat loss Potential hormonal benefits: emerging evidence suggests that fat mass reduction lowers aromatase activity, which may support healthier testosterone-to-estrogen balance For patients managing multiple metabolic conditions simultaneously, GLP-1/GIP weight loss therapy represents an opportunity to address root causes, rather than individual symptoms, through a single medically supervised intervention

PMID 16330288
What is the average weight loss with Tirzepatide
Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: multimodal Preventive Trial for Alzheimer's Disease (MIND-AD(mini))